1. Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX)
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) takes the top spot on this list of the top small-cap biotech stocks to buy now because it gives investors something many biotech companies cannot provide: profitability, commercial execution, and rare disease exposure in one package. Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is a rare disease-focused pharmaceutical company, and its position at No. 1 reflects the fact that not every attractive biotech story needs to be a pre-revenue clinical gamble.
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is the kind of name that can appeal to investors who want biotech exposure but also want a company with actual business performance. Many small-cap biotech stocks are valued mostly on what might happen in the future. Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), on the other hand, has already shown that it can execute commercially. That makes it a strong fit for searches such as best small-cap biotech stocks, profitable biotech stocks, rare disease stocks, small-cap healthcare stocks with earnings growth, and biotech stocks with strong fundamentals.
The company has also gained outside recognition. Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) was recognized on Forbes’ 2026 list of America’s most successful small-cap companies, with the ranking based on factors such as earnings growth, sales growth, return on equity, and total stock return. That recognition matters because it places Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) in a different category from many speculative biotech names. It is not only a science story. It is also a business execution story.
Rare disease remains one of the most attractive areas in specialty pharmaceuticals. These markets may be smaller than mass-market conditions, but they often have high unmet need, limited competition, and strong patient urgency. Companies that successfully serve rare disease communities can build durable businesses if they maintain strong access, physician relationships, and product performance. Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) fits that mold.
The top ranking also reflects balance. Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) may not have the same explosive binary catalyst profile as a clinical-stage oncology stock, but it offers something more grounded. It has profitability, revenue, and rare disease exposure. In a biotech sector where many stocks can rise or fall dramatically based on trial data, a profitable commercial-stage company can provide a different kind of appeal.
That does not mean Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is risk-free. No biotech stock is. The company still faces competition, reimbursement dynamics, regulatory risk, product concentration concerns, and the need to keep growing. But compared with many small-cap biotech names, Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) offers a more mature and financially established profile.
For investors searching for the best small-cap biotech stocks to buy now, Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) stands out because it combines profitability with rare disease focus and commercial execution. In a sector where hype can sometimes outrun fundamentals, Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) earns the No. 1 spot because it brings both a biotech growth story and a real operating business.
READ ALSO: Top 5 Best Biotech Stocks To Watch Now and Top 5 Biotech Stocks to Buy With Up to 215% Projected EPS Growth.
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
